54 records found.
Sep 23, 2019
Halozyme To Participate In 2019 Cantor Global Healthcare Conference
Sep 13, 2019
Positive Results Announced From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme's Enhanze® Drug Delivery Technology
Aug 06, 2019
Halozyme Reports Second Quarter 2019 Results
Jul 23, 2019
Halozyme To Host Second Quarter 2019 Financial Results Webcast And Conference Call
Jul 19, 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Jul 17, 2019
Halozyme Announces First Clinical Dosing In argenx's Phase 1 Trial Of Efgartigimod (ARGX-113) With ENHANZE® Drug Delivery Technology
Jul 12, 2019
Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology
Jun 25, 2019
Halozyme Announces CRADA With National Institute of Allergy and Infectious Diseases For Use Of ENHANZE® Drug Delivery Technology
May 22, 2019
Halozyme Announces argenx Has Selected Second Target Under ENHANZE® Technology Collaboration And License Agreement
May 13, 2019
Halozyme To Participate In Bank of America Merrill Lynch Health Care Conference 2019
May 07, 2019
Halozyme Reports First Quarter 2019 Results
Mar 04, 2019
Halozyme To Participate In Upcoming Investor Conferences
Feb 28, 2019
Halozyme Announces FDA Approval Of Herceptin Hylecta(TM)
Feb 21, 2019
Halozyme Reports Fourth Quarter And Full-Year 2018 Results
Feb 07, 2019
Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call
Feb 04, 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
Jan 09, 2019
Halozyme Provides 2019 Pipeline Update And Financial Guidance At 37th Annual JP Morgan Healthcare Conference
Dec 26, 2018
Halozyme Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference
Nov 06, 2018
Halozyme Names Albert Kildani As Vice President Investor Relations And Corporate Communications
Oct 30, 2018
Halozyme Licenses New ENHANZE® Targets For $25 Million Upfront Payment, Future Milestones And Royalties

Pages